201P Afatinib for EGFR, HER2 or HER3 mutated solid tumors: A phase II Belgian precision study.
Saved in:
| Title: | 201P Afatinib for EGFR, HER2 or HER3 mutated solid tumors: A phase II Belgian precision study. |
|---|---|
| Authors: | Decoster, L.1 (AUTHOR), Aftimos, P.G.2 (AUTHOR), Rottey, S.3 (AUTHOR), Prenen, H.4 (AUTHOR), Collignon, J.J.5 (AUTHOR), Mebis, J.6 (AUTHOR), Canon, J-L.7 (AUTHOR), Fastenaekels, V.8 (AUTHOR), Cappoen, N.8 (AUTHOR), Joris, S.R.8 (AUTHOR), De Grève, J.9 (AUTHOR) |
| Source: | Annals of Oncology. 2023 Supplement 2, Vol. 34, pS262-S262. 1p. |
| Database: | Academic Search Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 173099517 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: 201P Afatinib for EGFR, HER2 or HER3 mutated solid tumors: A phase II Belgian precision study. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Decoster%2C+L%2E%22">Decoster, L.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Aftimos%2C+P%2EG%2E%22">Aftimos, P.G.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Rottey%2C+S%2E%22">Rottey, S.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Prenen%2C+H%2E%22">Prenen, H.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Collignon%2C+J%2EJ%2E%22">Collignon, J.J.</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mebis%2C+J%2E%22">Mebis, J.</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Canon%2C+J-L%2E%22">Canon, J-L.</searchLink><relatesTo>7</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Fastenaekels%2C+V%2E%22">Fastenaekels, V.</searchLink><relatesTo>8</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Cappoen%2C+N%2E%22">Cappoen, N.</searchLink><relatesTo>8</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Joris%2C+S%2ER%2E%22">Joris, S.R.</searchLink><relatesTo>8</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22De+Grève%2C+J%2E%22">De Grève, J.</searchLink><relatesTo>9</relatesTo> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Annals+of+Oncology%22">Annals of Oncology</searchLink>. 2023 Supplement 2, Vol. 34, pS262-S262. 1p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=173099517 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.annonc.2023.09.2924 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 1 StartPage: S262 Titles: – TitleFull: 201P Afatinib for EGFR, HER2 or HER3 mutated solid tumors: A phase II Belgian precision study. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Decoster, L. – PersonEntity: Name: NameFull: Aftimos, P.G. – PersonEntity: Name: NameFull: Rottey, S. – PersonEntity: Name: NameFull: Prenen, H. – PersonEntity: Name: NameFull: Collignon, J.J. – PersonEntity: Name: NameFull: Mebis, J. – PersonEntity: Name: NameFull: Canon, J-L. – PersonEntity: Name: NameFull: Fastenaekels, V. – PersonEntity: Name: NameFull: Cappoen, N. – PersonEntity: Name: NameFull: Joris, S.R. – PersonEntity: Name: NameFull: De Grève, J. IsPartOfRelationships: – BibEntity: Dates: – D: 02 M: 10 Text: 2023 Supplement 2 Type: published Y: 2023 Identifiers: – Type: issn-print Value: 09237534 Numbering: – Type: volume Value: 34 Titles: – TitleFull: Annals of Oncology Type: main |
| ResultId | 1 |
